GENomic PROfilation for Therapeutic Purposes in SARComas and Molecular Tumor Board (MTB): Retrospective/Prospective Study in Referral Centers

Last updated: October 6, 2023
Sponsor: Regina Elena Cancer Institute
Overall Status: Active - Recruiting

Phase

N/A

Condition

Sarcoma

Treatment

N/A

Clinical Study ID

NCT06076070
RS1607/21
  • All Genders

Study Summary

Multicenter noninterventional, translational study, retrospective/prospective designed in order to assess the aptitude to the use of genomic profiling methods for therapeutic purposes and evaluation by the institutional Molecular Tumor Board (MTB) of sarcoma patients with metastatic/locally advanced disease that is inoperable with no viable therapeutic alternatives or with histotypes known to be resistant to available in-label medical treatments and without already therapeutically validated driver mutations.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Sarcoma patients of any age (inclusion of centers pediatric)

  • Patients with any histotype of soft tissue sarcomas and bone

  • Patients at any stage of the treatment pathway for disease that is localized or metastatic/inoperable

  • Availability of follow-up data

  • Written informed consent (prospective part/patients in follow-up)

Study Design

Total Participants: 10
Study Start date:
May 25, 2022
Estimated Completion Date:
May 25, 2024

Connect with a study center

  • "Regina Elena" National Cancer Institute

    Rome, 00144
    Italy

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.